secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2022-04-27T23:59:59+00:00
Accession:  0001564590-22-015873
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences reports positive Phase 3 ORCA-2 results; cytisinicline shows 6-8x odds of smoking abstinence
--------------------------------------------------------------------------------

- Primary endpoints met: 12-week cytisinicline had 32.6% abstinence vs 7.0% placebo (OR 6.3, p<0.0001); 6-week had 25.3% vs 4.4% (OR 8.0, p<0.0001).
- Secondary continuous abstinence weeks 9-24: 21.1% for 12-week arm vs 4.8% placebo (OR 5.3, p<0.0001); weeks 3-24: 8.9% vs 2.6% (OR 3.7, p=0.0016).
- Well tolerated; no treatment-related serious adverse events. Most common AEs (>5%): insomnia, abnormal dreams, headache, nausea.
- SVB approved remaining $10M of $25M debt facility; terms: interest at greater of 3.5% or WSJ prime, interest-only through Apr 2024, then 24-month amortization.
- Facility available through Apr 30, 2023; no amounts drawn at close; discretionary draws allowed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000156459022015873/0001564590-22-015873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000156459022015873/achv-8k_20220426.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-015873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer